Hodgkin and Non-Hodgkin Lymphoma | Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma — What Clinicians Want to Know

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL)  Introduction (0:00) Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36) Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10) Dr Friedberg presentation (11:54) Follicular Lymphoma  Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07) Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11) Dr Nastoupil presentation (38:36) Hodgkin Lymphoma  Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21) Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21) Dr Smith presentation (1:10:17) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma   Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with “double hit” DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56) Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10) Dr Maloney presentation (1:25:24) Mantle Cell Lymphoma (MCL)  Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10) Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47) Dr Kahl presentation (1:45:29) CME information and select publications